JP2008513012A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008513012A5 JP2008513012A5 JP2007532436A JP2007532436A JP2008513012A5 JP 2008513012 A5 JP2008513012 A5 JP 2008513012A5 JP 2007532436 A JP2007532436 A JP 2007532436A JP 2007532436 A JP2007532436 A JP 2007532436A JP 2008513012 A5 JP2008513012 A5 JP 2008513012A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- oligonucleotide
- seq
- virus
- targeting sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 51
- 108091034117 Oligonucleotide Proteins 0.000 claims description 35
- 230000008685 targeting Effects 0.000 claims description 18
- 241000700605 Viruses Species 0.000 claims description 14
- 241000710781 Flaviviridae Species 0.000 claims description 9
- 229910052739 hydrogen Inorganic materials 0.000 claims description 9
- 239000001257 hydrogen Substances 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 9
- 239000004475 Arginine Substances 0.000 claims description 8
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 8
- 230000000295 complement effect Effects 0.000 claims description 8
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims description 8
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 8
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 7
- MHCMWGPPLOSCJY-UHFFFAOYSA-N 4-$l^{1}-azanylmorpholine Chemical compound [N]N1CCOCC1 MHCMWGPPLOSCJY-UHFFFAOYSA-N 0.000 claims description 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 6
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims description 6
- 229910052799 carbon Inorganic materials 0.000 claims description 6
- 241001493065 dsRNA viruses Species 0.000 claims description 6
- 229910052698 phosphorus Inorganic materials 0.000 claims description 6
- 239000011574 phosphorus Substances 0.000 claims description 6
- 229920001184 polypeptide Polymers 0.000 claims description 6
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 6
- 102000040650 (ribonucleotides)n+m Human genes 0.000 claims description 5
- 241000711573 Coronaviridae Species 0.000 claims description 5
- KDCGOANMDULRCW-UHFFFAOYSA-N Purine Natural products N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 claims description 5
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims description 5
- 125000003545 alkoxy group Chemical group 0.000 claims description 5
- 125000003282 alkyl amino group Chemical group 0.000 claims description 5
- 125000000217 alkyl group Chemical group 0.000 claims description 5
- ANCLJVISBRWUTR-UHFFFAOYSA-N diaminophosphinic acid Chemical compound NP(N)(O)=O ANCLJVISBRWUTR-UHFFFAOYSA-N 0.000 claims description 5
- 108091033319 polynucleotide Proteins 0.000 claims description 5
- 102000040430 polynucleotide Human genes 0.000 claims description 5
- 239000002157 polynucleotide Substances 0.000 claims description 5
- IGFXRKMLLMBKSA-UHFFFAOYSA-N purine Chemical compound N1=C[N]C2=NC=NC2=C1 IGFXRKMLLMBKSA-UHFFFAOYSA-N 0.000 claims description 5
- 125000005309 thioalkoxy group Chemical group 0.000 claims description 5
- 108091027305 Heteroduplex Proteins 0.000 claims description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
- 238000010494 dissociation reaction Methods 0.000 claims description 3
- 230000005593 dissociations Effects 0.000 claims description 3
- 239000002773 nucleotide Substances 0.000 claims 9
- 210000004027 cell Anatomy 0.000 claims 5
- -1 nucleotide compound Chemical class 0.000 claims 5
- 125000003729 nucleotide group Chemical group 0.000 claims 4
- 230000010076 replication Effects 0.000 claims 4
- 230000003612 virological effect Effects 0.000 claims 3
- 101710163270 Nuclease Proteins 0.000 claims 2
- 230000000903 blocking effect Effects 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 241000725619 Dengue virus Species 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 241000710771 Tick-borne encephalitis virus Species 0.000 claims 1
- 241000710886 West Nile virus Species 0.000 claims 1
- 241000710772 Yellow fever virus Species 0.000 claims 1
- 230000000840 anti-viral effect Effects 0.000 claims 1
- 238000004590 computer program Methods 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 210000004962 mammalian cell Anatomy 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 238000010532 solid phase synthesis reaction Methods 0.000 claims 1
- 229940051021 yellow-fever virus Drugs 0.000 claims 1
- 241001292006 Arteriviridae Species 0.000 description 1
- 241001533362 Astroviridae Species 0.000 description 1
- 241000714198 Caliciviridae Species 0.000 description 1
- 241001122120 Hepeviridae Species 0.000 description 1
- 241000710924 Togaviridae Species 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US61106304P | 2004-09-16 | 2004-09-16 | |
| US60/611,063 | 2004-09-16 | ||
| US11/226,995 US8129352B2 (en) | 2004-09-16 | 2005-09-14 | Antisense antiviral compound and method for treating ssRNA viral infection |
| US11/226,995 | 2005-09-14 | ||
| PCT/US2005/032815 WO2006033933A2 (en) | 2004-09-16 | 2005-09-15 | Antisense antiviral compound and method for treating ssrna viral infection |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008513012A JP2008513012A (ja) | 2008-05-01 |
| JP2008513012A5 true JP2008513012A5 (enExample) | 2011-12-22 |
| JP5425396B2 JP5425396B2 (ja) | 2014-02-26 |
Family
ID=36074482
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007532436A Expired - Fee Related JP5425396B2 (ja) | 2004-09-16 | 2005-09-15 | アンチセンス抗ウイルス化合物及びｓｓＲＮＡウイルス感染を治療する方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (4) | US8129352B2 (enExample) |
| EP (1) | EP1802777B1 (enExample) |
| JP (1) | JP5425396B2 (enExample) |
| AU (1) | AU2005287160C1 (enExample) |
| CA (1) | CA2579815C (enExample) |
| WO (1) | WO2006033933A2 (enExample) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2351844B1 (en) * | 2003-04-29 | 2014-06-11 | Sarepta Therapeutics, Inc. | Compositions for enhancing transport and antisense efficacy of nucleic acid analog into cells |
| EP1668145A4 (en) * | 2003-08-07 | 2010-03-10 | Avi Biopharma Inc | SENSE ANTIVIRUS COMPOUND AND METHOD FOR TREATING SSRNA VIRUS INFECTION |
| US20050222068A1 (en) * | 2003-10-23 | 2005-10-06 | Mourich Dan V | Method and antisense composition for selective inhibition of HIV infection in hematopoietic cells |
| US20050171044A1 (en) * | 2003-12-24 | 2005-08-04 | Stein David A. | Oligonucleotide compound and method for treating nidovirus infections |
| US20050288246A1 (en) | 2004-05-24 | 2005-12-29 | Iversen Patrick L | Peptide conjugated, inosine-substituted antisense oligomer compound and method |
| ATE498685T1 (de) | 2004-06-28 | 2011-03-15 | Univ Western Australia | Antisense-oligonukleotide zur induktion von exon- skipping sowie verfahren zur verwendung davon |
| US8129352B2 (en) | 2004-09-16 | 2012-03-06 | Avi Biopharma, Inc. | Antisense antiviral compound and method for treating ssRNA viral infection |
| US8357664B2 (en) | 2004-10-26 | 2013-01-22 | Avi Biopharma, Inc. | Antisense antiviral compound and method for treating influenza viral infection |
| US7524829B2 (en) * | 2004-11-01 | 2009-04-28 | Avi Biopharma, Inc. | Antisense antiviral compounds and methods for treating a filovirus infection |
| US8067571B2 (en) | 2005-07-13 | 2011-11-29 | Avi Biopharma, Inc. | Antibacterial antisense oligonucleotide and method |
| WO2007030576A2 (en) * | 2005-09-08 | 2007-03-15 | Avi Biopharma, Inc. | Antisense antiviral compound and method for treating picornavirus infection |
| US8524676B2 (en) * | 2005-09-08 | 2013-09-03 | Sarepta Therapeutics, Inc. | Method for treating enterovirus or rhinovirus infection using antisense antiviral compounds |
| US8501704B2 (en) | 2005-11-08 | 2013-08-06 | Sarepta Therapeutics, Inc. | Immunosuppression compound and treatment method |
| ES2645410T3 (es) * | 2006-05-10 | 2017-12-05 | Sarepta Therapeutics, Inc. | Análogos de oligonucleótidos que tienen enlaces intersubunitarios catiónicos |
| US8785407B2 (en) * | 2006-05-10 | 2014-07-22 | Sarepta Therapeutics, Inc. | Antisense antiviral agent and method for treating ssRNA viral infection |
| CN101821390A (zh) * | 2007-06-14 | 2010-09-01 | 米尔克斯治疗有限责任公司 | 用于调节靶rna活性的寡核苷酸 |
| US20100016215A1 (en) | 2007-06-29 | 2010-01-21 | Avi Biopharma, Inc. | Compound and method for treating myotonic dystrophy |
| JP5864100B2 (ja) * | 2007-06-29 | 2016-02-17 | サレプタ セラピューティクス インコーポレイテッド | 組織特異的ペプチドコンジュゲートおよび方法 |
| TR201902952T4 (tr) | 2008-10-24 | 2019-03-21 | Sarepta Therapeutics Inc | Dmd için ekson atlama bileşimleri. |
| WO2010080554A1 (en) * | 2008-12-17 | 2010-07-15 | Avi Biopharma, Inc. | Antisense compositions and methods for modulating contact hypersensitivity or contact dermatitis |
| US20110269665A1 (en) | 2009-06-26 | 2011-11-03 | Avi Biopharma, Inc. | Compound and method for treating myotonic dystrophy |
| CA2780563C (en) | 2009-11-12 | 2025-05-06 | Univ Western Australia | Antisense Molecules and Methods for Treating Pathologies |
| WO2011060320A1 (en) | 2009-11-13 | 2011-05-19 | Avi Biopharma, Inc. | Antisense antiviral compound and method for treating influenza viral infection |
| EP2576574A2 (en) | 2010-05-28 | 2013-04-10 | Sarepta Therapeutics, Inc. | Oligonucleotide analogues having modified intersubunit linkages and/or terminal groups |
| US8198429B2 (en) | 2010-08-09 | 2012-06-12 | Avi Biopharma, Inc. | Antisense antiviral compounds and methods for treating a filovirus infection |
| WO2012031243A2 (en) | 2010-09-03 | 2012-03-08 | Avi Biopharma, Inc. | dsRNA MOLECULES COMPRISING OLIGONUCLEOTIDE ANALOGS HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS |
| US9161948B2 (en) | 2011-05-05 | 2015-10-20 | Sarepta Therapeutics, Inc. | Peptide oligonucleotide conjugates |
| KR102183273B1 (ko) | 2011-05-05 | 2020-11-27 | 사렙타 쎄러퓨틱스, 인코퍼레이티드 | 펩타이드 올리고뉴클레오타이드 접합체 |
| CN108864192A (zh) | 2011-11-18 | 2018-11-23 | 萨勒普塔医疗公司 | 功能改性的寡核苷酸及其亚单元 |
| US9920085B2 (en) * | 2012-03-20 | 2018-03-20 | Sarepta Therapeutics, Inc. | Boronic acid conjugates of oligonucleotide analogues |
| NZ775701A (en) | 2013-03-14 | 2022-08-26 | Sarepta Therapeutics Inc | Exon skipping compositions for treating muscular dystrophy |
| NZ732507A (en) | 2013-03-15 | 2018-08-31 | Sarepta Therapeutics Inc | Improved compositions for treating muscular dystrophy |
| CN103235902B (zh) * | 2013-04-18 | 2016-03-09 | 山东建筑大学 | 包含假结的rna结构预测方法 |
| WO2016142449A1 (en) * | 2015-03-11 | 2016-09-15 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of filovirus infections |
| US11020417B2 (en) | 2015-06-04 | 2021-06-01 | Sarepta Therapeutics, Inc | Methods and compounds for treatment of lymphocyte-related diseases and conditions |
| EP3538108A4 (en) | 2016-11-10 | 2020-06-17 | Oyagen, Inc. | METHODS OF TREATING AND INHIBITING EBOLA VIRUS INFECTION |
| MD3554553T2 (ro) | 2016-12-19 | 2022-10-31 | Sarepta Therapeutics Inc | Conjugați de oligomeri de omitere a exonului, pentru distrofie musculară |
| JP7596148B2 (ja) * | 2018-03-16 | 2024-12-09 | サレプタ セラピューティクス， インコーポレイテッド | アンチセンス送達用キメラペプチド |
| US12215382B2 (en) | 2019-03-01 | 2025-02-04 | The General Hospital Corporation | Liver protective MARC variants and uses thereof |
| CA3153902A1 (en) | 2019-10-16 | 2021-04-22 | Pardis SABETI | Engineered muscle targeting compositions |
| WO2021158248A1 (en) * | 2020-02-04 | 2021-08-12 | Oyagen, Inc. | Method for treating coronavirus infections |
| WO2021211572A1 (en) * | 2020-04-14 | 2021-10-21 | Oregon State University | Antisense therapeutics for the treatment of coronavirus |
| WO2024016003A2 (en) | 2022-07-14 | 2024-01-18 | The Broad Institute, Inc. | Aav capsids that enable cns-wide gene delivery through interactions with the transferrin receptor |
| WO2025155923A1 (en) | 2024-01-17 | 2025-07-24 | The Broad Institute, Inc. | Aav capsid modifications that enable improved cns-wide gene delivery through interactions with the transferrin receptor |
| WO2025217163A2 (en) | 2024-04-08 | 2025-10-16 | The Broad Institute, Inc. | Novel aav capsids binding to human cd59 |
| WO2025217174A1 (en) | 2024-04-08 | 2025-10-16 | The Broad Institute, Inc. | Aav capsid modifications that enable improved cns-wide gene delivery through interactions with carbonic anhydrase iv |
Family Cites Families (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5521063A (en) | 1985-03-15 | 1996-05-28 | Antivirals Inc. | Polynucleotide reagent containing chiral subunits and methods of use |
| US5185444A (en) | 1985-03-15 | 1993-02-09 | Anti-Gene Deveopment Group | Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages |
| US5166315A (en) | 1989-12-20 | 1992-11-24 | Anti-Gene Development Group | Sequence-specific binding polymers for duplex nucleic acids |
| DE3687030T2 (de) | 1985-03-15 | 1993-03-11 | Eugene Stirchak | Stereoregulare polynukleotiden bindende polymere. |
| US5034506A (en) | 1985-03-15 | 1991-07-23 | Anti-Gene Development Group | Uncharged morpholino-based polymers having achiral intersubunit linkages |
| US5217866A (en) | 1985-03-15 | 1993-06-08 | Anti-Gene Development Group | Polynucleotide assay reagent and method |
| US5506337A (en) | 1985-03-15 | 1996-04-09 | Antivirals Inc. | Morpholino-subunit combinatorial library and method |
| US5194428A (en) | 1986-05-23 | 1993-03-16 | Worcester Foundation For Experimental Biology | Inhibition of influenza virus replication by oligonucleotide phosphorothioates |
| US5749847A (en) | 1988-01-21 | 1998-05-12 | Massachusetts Institute Of Technology | Delivery of nucleotides into organisms by electroporation |
| US5852188A (en) | 1990-01-11 | 1998-12-22 | Isis Pharmaceuticals, Inc. | Oligonucleotides having chiral phosphorus linkages |
| BR9106747A (pt) | 1990-08-14 | 1993-07-20 | Isis Pharmaceuticals Inc | Oligonucleotideo ou analogo de oligonucleotideo e processo para tratamento de um animal suspeito de estar infectado por virus da influenza |
| US5495006A (en) | 1991-09-27 | 1996-02-27 | Allelix Biopharmaceuticals, Inc. | Antiviral polynucleotide conjugates |
| US5576302A (en) | 1991-10-15 | 1996-11-19 | Isis Pharmaceuticals, Inc. | Oligonucleotides for modulating hepatitis C virus having phosphorothioate linkages of high chiral purity |
| JPH07502658A (ja) | 1991-12-23 | 1995-03-23 | バイエル コーポレイション | 溶液相サンドイッチハイブリダイゼーションアッセイに用いるためのｈａｖプローブ |
| US20030171311A1 (en) | 1998-04-27 | 2003-09-11 | Lawrence Blatt | Enzymatic nucleic acid treatment of diseases or conditions related to hepatitis C virus infection |
| US6391542B1 (en) | 1992-09-10 | 2002-05-21 | Isis Pharmaceuticals, Inc. | Compositions and methods for treatment of Hepatitis C virus-associated diseases |
| US6174868B1 (en) | 1992-09-10 | 2001-01-16 | Isis Pharmaceuticals, Inc. | Compositions and methods for treatment of hepatitis C virus-associated diseases |
| CA2159639A1 (en) | 1993-04-02 | 1994-10-13 | Vincent J. Miles | Method for selective inactivation of viral replication |
| US6824976B1 (en) | 1993-04-02 | 2004-11-30 | Rigel Pharmaceuticals, Inc. | Method for selective inactivation of viral replication |
| WO1995007265A1 (en) * | 1993-09-10 | 1995-03-16 | E.I. Du Pont De Nemours And Company | Improved process for preparing 2-amino-4,6-dichloropyrimidine |
| US5801154A (en) | 1993-10-18 | 1998-09-01 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of multidrug resistance-associated protein |
| US6060456A (en) | 1993-11-16 | 2000-05-09 | Genta Incorporated | Chimeric oligonucleoside compounds |
| US5734039A (en) * | 1994-09-15 | 1998-03-31 | Thomas Jefferson University | Antisense oligonucleotides targeting cooperating oncogenes |
| US5989904A (en) | 1994-10-11 | 1999-11-23 | The Regents Of The University Of California | Selective inhibition of internally initiated RNA translation |
| DE69633780T3 (de) * | 1995-04-18 | 2011-05-05 | Biosite Incorporated, San Diego | Verfahren zum assay von troponin i und t und komplexen von troponin i und t und auswahl von antikörpern zur verwendung in immunoassays |
| GB9510718D0 (en) | 1995-05-26 | 1995-07-19 | Sod Conseils Rech Applic | Antisense oligonucleotides |
| US5955318A (en) | 1995-08-14 | 1999-09-21 | Abbott Laboratories | Reagents and methods useful for controlling the translation of hepatitis GBV proteins |
| US6214555B1 (en) | 1996-05-01 | 2001-04-10 | Visible Genetics Inc. | Method compositions and kit for detection |
| WO1998012312A1 (en) | 1996-09-18 | 1998-03-26 | Vanderbilt University | Antisense gene therapy for rna viruses |
| EP0856579A1 (en) | 1997-01-31 | 1998-08-05 | BIOGNOSTIK GESELLSCHAFT FÜR BIOMOLEKULARE DIAGNOSTIK mbH | An antisense oligonucleotide preparation method |
| AU734827B2 (en) | 1997-05-21 | 2001-06-21 | Board Of Trustees Of The Leland Stanford Junior University | Composition and method for enhancing transport across biological membranes |
| JP3171827B2 (ja) * | 1997-08-04 | 2001-06-04 | 株式会社先端生命科学研究所 | ウイルスの検出又は測定方法 |
| US6133246A (en) | 1997-08-13 | 2000-10-17 | Isis Pharmaceuticals Inc. | Antisense oligonucleotide compositions and methods for the modulation of JNK proteins |
| US6228579B1 (en) | 1997-11-14 | 2001-05-08 | San Diego State University Foundation | Method for identifying microbial proliferation genes |
| US6258570B1 (en) | 1998-04-17 | 2001-07-10 | University Of Pittsburgh | PCR assay for bacterial and viral meningitis |
| US20030044979A1 (en) | 2001-04-05 | 2003-03-06 | Isis Pharmaceuticals Inc. | Antisense modulation of phospholipid scramblase I expression |
| JP4777515B2 (ja) | 1998-10-26 | 2011-09-21 | エイブイアイ バイオファーマ， インコーポレイテッド | ｐ５３モルホリノに基づくアンチセンス |
| US7094765B1 (en) | 1999-01-29 | 2006-08-22 | Avi Biopharma, Inc. | Antisense restenosis composition and method |
| EP1173561A2 (en) | 1999-01-29 | 2002-01-23 | Avi Biopharma, Inc. | Non-invasive method for detecting target rna |
| US6669951B2 (en) | 1999-08-24 | 2003-12-30 | Cellgate, Inc. | Compositions and methods for enhancing drug delivery across and into epithelial tissues |
| US6881825B1 (en) | 1999-09-01 | 2005-04-19 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Identication of peptides that facilitate uptake and cytoplasmic and/or nuclear transport of proteins, DNA and virues |
| US6521438B1 (en) | 1999-11-05 | 2003-02-18 | North Carolina State University | Chemoreceptors in plant parasitic nematodes |
| US20030095953A1 (en) | 1999-11-12 | 2003-05-22 | Myles C. Cabot | Methods of reversing drug resistance in cancer cells |
| US6677153B2 (en) | 1999-11-29 | 2004-01-13 | Avi Biopharma, Inc. | Antisense antibacterial method and composition |
| EP1248813A2 (en) | 2000-01-04 | 2002-10-16 | Avi Biopharma, Inc. | Antisense antibacterial cell division composition and method |
| JP2003533986A (ja) | 2000-05-04 | 2003-11-18 | エイブイアイ バイオファーマ， インコーポレイテッド | スプライス領域アンチセンス組成物および方法 |
| EP1301525B1 (en) | 2000-07-06 | 2015-09-02 | Sarepta Therapeutics, Inc. | Transforming growth factor beta (tgf-beta) blocking agent-treated stem cell composition and method |
| JP2004533204A (ja) | 2000-07-06 | 2004-11-04 | ビヨ・メリウー | 水性媒体の微生物学的品質の管理方法及びそれ用のキット |
| US6673917B1 (en) | 2000-09-28 | 2004-01-06 | University Of Ottawa | Antisense IAP nucleic acids and uses thereof |
| WO2002068637A2 (en) | 2000-10-20 | 2002-09-06 | Ribozyme Pharmaceuticals, Inc. | Nucleic acid-based treatment of diseases or conditions related to west nile virus infection |
| US6828105B2 (en) | 2001-10-16 | 2004-12-07 | Avi Biopharma, Inc. | Antisense antiviral agent and method for treating ssRNA viral infection |
| US20030224353A1 (en) | 2001-10-16 | 2003-12-04 | Stein David A. | Antisense antiviral agent and method for treating ssRNA viral infection |
| US6841675B1 (en) | 2002-06-13 | 2005-01-11 | The Regents Of The University Of California | Piperazine-based nucleic acid analogs |
| AU2003267785C1 (en) | 2002-09-13 | 2009-12-24 | Replicor, Inc. | Non-sequence complementary antiviral oligonucleotides |
| EP2977470B1 (en) | 2002-10-16 | 2018-01-03 | Gen-Probe Incorporated | Compositions and methods for detecting west nile virus |
| US7615629B2 (en) | 2002-12-31 | 2009-11-10 | Sigma-Aldrich Co. | Methods and compositions for the tandem synthesis of two or more oligonucleotides on the same solid support |
| EP2351844B1 (en) | 2003-04-29 | 2014-06-11 | Sarepta Therapeutics, Inc. | Compositions for enhancing transport and antisense efficacy of nucleic acid analog into cells |
| ATE491791T1 (de) * | 2003-08-05 | 2011-01-15 | Avi Biopharma Inc | Oligonukleotidanalog und verfahren zur behandlung von flavivirusinfektionen |
| EP1668145A4 (en) | 2003-08-07 | 2010-03-10 | Avi Biopharma Inc | SENSE ANTIVIRUS COMPOUND AND METHOD FOR TREATING SSRNA VIRUS INFECTION |
| US20050171044A1 (en) | 2003-12-24 | 2005-08-04 | Stein David A. | Oligonucleotide compound and method for treating nidovirus infections |
| US8129352B2 (en) | 2004-09-16 | 2012-03-06 | Avi Biopharma, Inc. | Antisense antiviral compound and method for treating ssRNA viral infection |
| US8357664B2 (en) | 2004-10-26 | 2013-01-22 | Avi Biopharma, Inc. | Antisense antiviral compound and method for treating influenza viral infection |
| US7524829B2 (en) | 2004-11-01 | 2009-04-28 | Avi Biopharma, Inc. | Antisense antiviral compounds and methods for treating a filovirus infection |
| US8067571B2 (en) * | 2005-07-13 | 2011-11-29 | Avi Biopharma, Inc. | Antibacterial antisense oligonucleotide and method |
| US8524676B2 (en) | 2005-09-08 | 2013-09-03 | Sarepta Therapeutics, Inc. | Method for treating enterovirus or rhinovirus infection using antisense antiviral compounds |
| WO2007030576A2 (en) | 2005-09-08 | 2007-03-15 | Avi Biopharma, Inc. | Antisense antiviral compound and method for treating picornavirus infection |
| DE602007006457D1 (de) | 2006-03-07 | 2010-06-24 | Avi Biopharma Inc | Antivirale antisense-verbindung und verfahren zur behandlung von arenavirus-infektion |
| US8785407B2 (en) | 2006-05-10 | 2014-07-22 | Sarepta Therapeutics, Inc. | Antisense antiviral agent and method for treating ssRNA viral infection |
| ES2645410T3 (es) | 2006-05-10 | 2017-12-05 | Sarepta Therapeutics, Inc. | Análogos de oligonucleótidos que tienen enlaces intersubunitarios catiónicos |
| JP5864100B2 (ja) | 2007-06-29 | 2016-02-17 | サレプタ セラピューティクス インコーポレイテッド | 組織特異的ペプチドコンジュゲートおよび方法 |
-
2005
- 2005-09-14 US US11/226,995 patent/US8129352B2/en not_active Expired - Fee Related
- 2005-09-15 WO PCT/US2005/032815 patent/WO2006033933A2/en not_active Ceased
- 2005-09-15 EP EP05796604A patent/EP1802777B1/en not_active Expired - Lifetime
- 2005-09-15 CA CA2579815A patent/CA2579815C/en not_active Expired - Fee Related
- 2005-09-15 AU AU2005287160A patent/AU2005287160C1/en not_active Ceased
- 2005-09-15 JP JP2007532436A patent/JP5425396B2/ja not_active Expired - Fee Related
-
2006
- 2006-05-10 US US11/432,031 patent/US8084433B2/en not_active Expired - Fee Related
-
2011
- 2011-12-22 US US13/335,450 patent/US8906872B2/en not_active Expired - Fee Related
-
2014
- 2014-11-06 US US14/535,092 patent/US10479996B2/en not_active Expired - Lifetime
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008513012A5 (enExample) | ||
| JP5425396B2 (ja) | アンチセンス抗ウイルス化合物及びｓｓＲＮＡウイルス感染を治療する方法 | |
| CN109843902B (zh) | 用于B型肝炎病毒感染的RNAi剂 | |
| Warren et al. | Advanced morpholino oligomers: a novel approach to antiviral therapy | |
| US8785407B2 (en) | Antisense antiviral agent and method for treating ssRNA viral infection | |
| Shetty et al. | Hepatitis C virus RNA: molecular switches mediated by long-range RNA–RNA interactions? | |
| JP2005507660A (ja) | ｓｓＲＮＡウイルス感染の処置のためのアンチセンス抗ウイルス剤および方法 | |
| CA2223645A1 (en) | Antisense inhibition of hepatitis b virus replication | |
| CN113507920A (zh) | 用于乙型肝炎病毒感染的RNAi剂 | |
| AU2004263124B2 (en) | Sense antiviral compound and method for treating ssRNA viral infection | |
| CN114846140A (zh) | 用于治疗hbv的靶向hbv的治疗性寡核苷酸和tlr7激动剂的药物组合 | |
| CN112534055A (zh) | 用于调节rtel1表达的寡核苷酸 | |
| Steger et al. | Viroid structure | |
| Hasturk et al. | A therapeutic approach for the hepatitis C virus: in silico design of an antisense oligonucleotide-based candidate capsid inhibitor | |
| Markosian et al. | Oligonucleotides and polyribonucleotides: a review of antiviral activity | |
| Manas et al. | Guanine quadruplexes and disease: Insight into mechanisms and therapeutic potential | |
| Khanna et al. | Genome-wide prediction and analysis of siRNA as potential antiviral agent against Hepatitis-C virus | |
| US9068160B2 (en) | Methods of producing an antisense viral particle population | |
| CN117737057A (zh) | 一种具有增强抗乙肝效果的小核酸序列以及其偶联物 | |
| HK40078456A (en) | Use of sbds inhibitors for treating hepatitis b virus infection | |
| HK40078459A (en) | Use of scamp3 inhibitors for treating hepatitis b virus infection | |
| HK40062579A (en) | Rnai agents for hepatitis b virus infection | |
| HK1100961B (en) | Antisense antiviral compound and method for treating ssrna viral infection | |
| HK40009627A (en) | Rnai agents for hepatitis b virus infection |